DekaBank Deutsche Girozentrale’s Heron Therapeutics HRTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-39,000	Closed	-$1.5M	–	1214
2019 Q1	$1.5M	Buy	+39,000	New	+$1.02M	0.01%	674
2018 Q4	–	Sell	-39,000	Closed	-$1.5M	–	1212
2018 Q3	$1.5M	Sell	39,000 -1,000	-3%	-$37.2K	0.01%	686
2018 Q2	$1.64M	Buy	+40,000	New	+$1.27M	0.01%	633

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

DekaBank Deutsche Girozentrale's HRTX Position: Q2 2019 in Review

DekaBank Deutsche Girozentrale sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 39,000 shares — an estimated $1.5M sold.

DekaBank Deutsche Girozentrale first reported a position in HRTX in Q2 2018 and held it in 3 quarters. The position peaked at $1.64M in Q2 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

DekaBank Deutsche Girozentrale reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 39,000 Heron Therapeutics shares in Q2 2019, an estimated $1.5M.
DekaBank Deutsche Girozentrale first reported a position in Heron Therapeutics in Q2 2018 and held it in 3 quarters.
DekaBank Deutsche Girozentrale's Heron Therapeutics position peaked at $1.64M in Q2 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2019, filed 1 Aug 2019.